General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-13 | 2024-03 | 0 | -1.64 | N/A | N/A |
2024-02-13 | 2023-12 | 0 | -2.64 | N/A | N/A |
2023-11-13 | 2023-09 | 0 | -2.76 | N/A | N/A |
2023-09-29 | 2023-06 | 0 | N/A | N/A | N/A |
2023-05-15 | 2023-03 | 0 | -2.72 | N/A | N/A |
2023-02-13 | 2022-12 | 0 | -3.4 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-25 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-08-10 | BOSTON MEGAN JOAN | Officer and Director | 25.93K | Purchase |
2023-08-10 | BUCHI J. KEVIN | Director | 52.10K | Purchase |
2021-12-08 | OLIVEIRA STEVEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Suvretta Capital Management, LLC | 769.00K | 3.12M | 30.19% |
2023-06-29 | Franklin Resources, Inc. | 588.24K | 2.39M | 23.09% |
2023-06-29 | Vanguard Group Inc | 4.40K | 17.83K | 0.17% |
2023-06-29 | Virtu Financial LLC | 3.11K | 12.61K | 0.12% |
2023-06-29 | Geode Capital Management, LLC | 2.84K | 11.50K | 0.11% |
2023-06-29 | Morgan Stanley | 2.27K | 9.21K | 0.09% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-07-30 | Franklin Strategic Series-Franklin Biotechnology Discove | 364.89K | 1.12M | 14.32% |
2023-06-29 | Vanguard Extended Market Index Fund | 4.40K | 17.83K | 0.17% |
2023-05-30 | Fidelity Extended Market Index Fund | 1.77K | 7.26K | 0.07% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 695.00 | 2.85K | 0.03% |
2023-05-30 | Fidelity Series Total Market Index Fund | 327.00 | 1.34K | 0.01% |
Dividend | Date |
---|---|
0.003 | 2018-06-01 |
Split | Date |
---|---|
1 : 17 | 2023-07-26 |
2 : 3 | 2020-04-15 |
1 : 10 | 2019-11-18 |
1 : 4 | 2015-06-16 |
$BNTC thanks for those cheap $1.38 shares paper hands….
None to short
No share left to short $BNTC
$BNTC no share left to short, pos is going down bad haha
1 Wall Street analysts have issued ratings and price targets for Benitec Biopharma in the last 12 months. Their average twelve-month price target is $14.00, predicting that the stock has a possible upside of 204.35%. The high price target for BNTC is $14.00 and the low price target for BNTC is $14.00. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
$BNTC This is a big deal
$BNTC We’ll finish the day above $5
Why is it halted ?
Ready for takeoff